APOE4 can raise the odds of late-onset Alzheimer's disease. Phoenix studies the interventions and everyday choices behind carriers who are doing better over time.
Issue 01 asks one question: what changed after APOE4 carriers changed their medications, supplements, sleep and daily habits? Here is what moved, who it moved for, and what else was going on at the time.
How to read this
Phoenix research is longitudinal and observational: we follow real APOE4 carriers over time and compare each member with their own earlier self, with no placebo group, no randomisation, and members choosing their own interventions.
That means these are strong signals pointing at what to test next, not proof of cause. Most nutrition, supplement and lifestyle research you read online has exactly the same design. The difference is that we say so, and we show you the confounders.
Read the full methods and limitsThis is what Phoenix can see that nobody else can. Each card is one real APOE4 carrier, their own before and after, and the number that moved.
Bloodwork cases clear a hard bar: a dated baseline, a logged start, a later blood test, and nothing else in that member's stack starting anywhere between the two draws. Phoenix members stack heavily, so most candidates fail that test. Sleep, device, habit and exercise cases are measured differently, against a member's own other days or nights, and each one states how many of those sit on each side.
Every sleep, device and habit case below was found twice, independently, by analysts who never saw each other's queries. Where their numbers disagreed, we dropped the case.
What the markers did after a member started a prescribed medication.
APOE4 3/4 · female · 60s
MEMBER #F05654Her statin cut her ApoB by 39.8% in 77 days.
Her baseline was drawn 35 days before she started. Her ApoB finished at 59 mg/dL; Phoenix now interprets that result against the cardiovascular risk tier reviewed for the member.
What else changed: Nothing else in her stack started between the two blood draws. This is the cleanest case in the issue.
Next study: Confirm dose and adherence, then repeat ApoB on a pre-set date.
Members log what they take and the day they start. These are the moves that followed.
Every case here moved a lipid or methylation marker in the direction a carrier wants, inside a window where nothing else in the stack changed.
APOE4 3/4 · female · 40s
MEMBER #340F1BHer probiotics took LDL from 98 to 66 mg/dL, triglycerides from 49 to 34, and total cholesterol from 199 to 171.
That is 32.7%, 30.6% and 14.1%. Three markers moving together inside one clean window is rarer, and more interesting, than any single large number.
What else changed: Nothing else started between the two draws. Her baseline was taken 3 days before she began, so the run-up is tight.
Next study: Repeat with a pre-set 12-week retest and a recorded strain and dose.
APOE4 3/4 · female · 50s
MEMBER #89E781Her creatine dropped her LDL 35.6% in 83 days, with total cholesterol down 15.3% alongside it.
Creatine is not a lipid intervention. Nobody went looking for this one, which is exactly why it is worth showing you.
What else changed: Nothing else started between the two draws. Diet, weight and training are not captured here, and any of them could be the real actor.
Next study: Recruit carriers already starting creatine, fix the retest date in advance, and capture weight and training alongside.
APOE4 4/4 · male · 50s
MEMBER #838B59His magnesium threonate pulled homocysteine down 28.8% in 64 days.
His triglycerides fell 15.6% over the same window, from 64 to 54 mg/dL.
What else changed: Nothing else started between the two draws. B-vitamin intake is not captured in this window and is the obvious alternative explanation.
Next study: Capture B12, folate and B6 at both ends, then repeat.
APOE4 4/4 · male · 40s
MEMBER #2AAC0FHis Lysoveta lifted HDL 18.7% in 67 days, and total cholesterol came down 10.4%.
Lysoveta is the LPC-DHA omega-3 built to cross a compromised APOE4 blood-brain barrier, so a lipid response is the expected place to look first.
What else changed: Nothing else started between the two draws, but his baseline sits 170 days before the start, which is a long run-up for anything to drift.
Next study: Pair with an Omega-3 Index at both ends. Phoenix currently has exactly one member with a repeat Omega-3 Index, which is a test-ordering gap, not a science one.
Objective wearable sleep, each member split against their own median bedtime. Their earlier nights versus their own later ones.
Across the 15 members with enough wearable nights to split, 14 slept less on their own later nights, losing about 96 minutes on average. Five of five men and nine of ten women. One went the other way, and we are saying so.
APOE4 3/4 · female
MEMBER #E7D3DAHer earlier nights ran 413.9 minutes of sleep. Her later ones, 296.6.
Her deep and REM sleep fell with it, from 180.8 minutes to 130.3.
What else changed: 16 earlier nights against 17 later ones. Nothing was assigned; the split is her own median bedtime, so this is her against herself.
Next study: Pre-plan alternating bedtime windows and hold the wearable constant.
APOE4 4/4 · male
MEMBER #B32EF0490.2 minutes against 405.6, and 56 of those extra minutes were deep or REM.
Deep plus REM ran 305.6 minutes against 249.8.
What else changed: 17 earlier nights against 18 later ones, split at his own median bedtime.
APOE4 4/4 · female
MEMBER #E9BC57431.8 minutes against 351.9 on her later nights.
Deep plus REM 196.6 against 153.1, a 22% difference in the sleep that does the clearing.
What else changed: 25 earlier nights against 28 later ones, split at her own median bedtime.
The ZenoWell taVNS device, compared on each member’s own use nights versus their own non-use nights.
Of the 40 members who logged device use, only two or three have real wearable data on the days they used it. The rest log through a flow that writes a fixed placeholder instead of a measurement. That is a hole in how the study was set up, not a verdict on the device, and it is the first thing Phoenix is fixing.
APOE4 4/4 · female · 60s
MEMBER #37CA49Her taVNS nights ran 139.4 minutes of deep and REM sleep against 71.4 on her non-use nights.
Her total sleep barely moved, up 4.2%, so this is a change in composition rather than duration. 60 use nights against 21 is one of the largest evidence bases in the issue.
What else changed: Her heart-rate variability was slightly lower on use nights, down 7%, even as her deep sleep doubled. We print that because it is what the data says.
Next study: Connect wearables before first use so there is a clean baseline to measure against.
APOE4 3/4 · female · 50s
MEMBER #A5A193522.4 minutes against 488.4, with 27 of the extra minutes deep or REM.
11 use nights against 17 non-use nights. A second, independent member pointing the same way.
What else changed: Small sample on the use side, and her non-use nights are not evenly spread across the study window.
What a member did, compared against their own other days, using their daily check-in ratings.
Among the 24 members carrying two copies of APOE4, 17 rated their sleep better on early-bedtime days and not one rated it worse. On mental sharpness, 10 improved and again nobody declined.
APOE4 4/4 · male · 30s
MEMBER #B8CAEBHis sleep quality runs 7.75 out of 10 on sauna nights against 5.63 on his other nights.
And it passes the test that matters most: it gets stronger the more evidence you demand. At three sauna days the gap is 1.70, at five 1.97, at ten 2.17. Noise does the opposite.
What else changed: 16 sauna days against 89 without. Sauna days may cluster on his easier days generally.
Next study: Pair the rating with wearable sleep stages, which do not always agree.
APOE4 4/4 · male · 60s
MEMBER #CE2BE1His calm runs 1.60 points higher on breathwork days.
At a three-day floor the gap is nearly zero. At five, 0.72. At ten, 1.32. At full sample, 1.60. A rising line like that is the signature of something real, and almost nothing else in this dataset does it. His sauna days show the same shape and land at 1.61.
What else changed: 34 breathwork days against 25 without. He often does sauna and breathwork together, so the two reinforce each other.
APOE4 4/4 · female · 60s
MEMBER #A1351DAlcohol costs her 1.6 points of sleep quality against her own other nights.
Her Mediterranean-keto days run 1.49 points better on the same rating. Her tags point in different directions, which is the best evidence we have that we are measuring her habits and not just her good weeks.
What else changed: 24 nights with alcohol against 32 without. The gap was larger in her early data and settled as more nights came in, so we quote the smaller later number.
Heart-rate variability and sleep on the days and nights around a logged workout.
APOE4 4/4 · male · 60s
MEMBER #8AFF6234.0 milliseconds against 29.0 on his non-training days.
Across 141 days, the largest evidence base of any exercise case here.
What else changed: Observational. What he does on training days differs in more ways than the training.
APOE4 4/4 · male · 50s
MEMBER #A705D1Next-day HRV rose 32%, from 25.9 to 34.2 milliseconds.
His deep and REM sleep on the night of a workout ran 42% lower. Both are true. A member deciding when to train deserves both halves.
What else changed: Workout timing is not captured, and it is the obvious thing that would explain the split.
Next study: Capture time of day, then test morning against evening training in the same member.
These grouped patterns come first because repetition across members is more informative than one person's result. Where a real alternative explanation exists, Phoenix names it beside the number.
Medication signal
n=4 · PHOENIX MEMBERS4 of 4 were followed by lower LDL or ApoB
The screen required a dated baseline, a logged start, a later blood test, and no other intervention start in the 30-day window around the statin start.
Strongest caveat: Observational. Dose, adherence, diet, weight change, and care outside Phoenix may still explain part of the movement.
Sleep-timing signal
n=15 · PHOENIX MEMBERS14 of 15 slept longer on their own earlier nights
The average difference was about 96 minutes, and it holds in both sexes: five of five men and nine of ten women. This replaces an earlier screen that found 8 of 8 at 54.6 minutes; the newer one covers more members and was reproduced independently by two analysts.
Strongest caveat: Not randomized. Schedule, stress, illness, travel, alcohol, and measurement coverage can affect both bedtime and sleep duration. One of the fifteen went the other way, and we would rather say so than round to fifteen of fifteen.
Sleep-and-day signal
n=32 · PHOENIX MEMBERSEnergy, mood, sharpness, and calm were higher after longer nights
Within-member comparisons linked objective sleep with the next daily check-in, reducing some between-person differences.
Routine-linked signal
n=4 · PHOENIX MEMBERS+0.57 energy and +0.60 wellbeing points
Each member was compared with their own explicitly missed days. All four member-level differences were positive for both energy and wellbeing.
Strongest caveat: Magnesium days also included 6.17 more logged interventions on average. This is more likely a whole-routine signal than an isolated magnesium effect.
These are within-member taken-versus-explicitly-missed-day differences. They are not isolated supplement effects. On focal taken days, members usually logged several other interventions too. Phoenix treats them as whole-routine leads for prospective testing.
Energy +0.28 · wellbeing +0.50 · sleep +0.64
On taken days: +8.07 other interventions on average.
Wellbeing +0.47 · sleep +0.42
On taken days: +6.82 other interventions on average.
Wellbeing +0.68 · sleep +0.52
On taken days: +9.33 other interventions on average.
Energy +0.37 · sleep +0.76
On taken days: +1.55 other interventions on average.
Energy +0.31 · wellbeing +0.81
On taken days: +13.71 other interventions on average.
Energy +0.55 · wellbeing +0.78 · sleep +0.67
On taken days: +11.40 other interventions on average.
A broad screen tested 263 supplement-biomarker pairs. None survived false-discovery correction.
Two omega-3 protocol bundles had large triglyceride falls, but there was no isolated anchored case and several opposite-direction cases.
Phoenix has 167 completed cognitive sessions, but no qualifying intervention-exposure-follow-up sequence yet.
All 86 experiment records carry zero linked verification tests, verification values, or direction-matched verdicts, and only three were ever logged day to day. Members declare an experiment and then do not run it.
Sunlight does nothing measurable to calm across 29 women, flat to slightly negative at every evidence threshold tested. It is one of the most-logged habits in Phoenix and one of the most universally recommended things in this field.
Phoenix was built by Dr. Kevin Tran, PharmD, an APOE4/4 carrier, because he needed this research too. We want to know what appears to help real carriers at home, at work, while travelling, under stress, and through imperfect weeks, not only under ideal conditions.
For a patient, a meaningful improvement can still matter when the mechanism is uncertain or partly contextual. That does not make every pattern true, safe, or caused by one intervention. Cost, side effects, interactions, clinician guidance, and the possibility of placebo or confounding still matter.
Randomized, placebo-controlled trials are essential for estimating whether an intervention causes an effect under controlled conditions. They take time and resources, and they deliberately study defined populations.
Phoenix asks a complementary question: what patterns appear in real APOE4 carriers living ordinary, disrupted lives? Our observations are faster and more personal, but they are also noisier and cannot replace controlled trials. The strongest result is a signal worth testing better, not a verdict.
In biomarker-confirmed Alzheimer's clinical-trial cohorts, 65% to 70% of participants carry APOE4. Yet even a good trial rarely answers the question each carrier faces at home: what works for me, in real life?
You can take ten supplements, change your diet, add a medication, and still not know what helped. Phoenix turns APOE4 evidence into one measured experiment, then learns from your result.
Stop guessing. Test one intervention. Make the next decision with better evidence.
More certainty for youGenetics · baseline · context · adherenceWhat should I test?
Clinical trials, research papers, Phoenix Member results, and your data become one candidate insight with a confidence level.
Phoenix AIAPOE4 evidence, personalized with your data.The evidence fits. Your personal response is still unknown.
How do I test it?
Set the outcome. Measure before. Track the test. Measure again.
Did it work for me?
If the result moves as expected, confidence may rise. If not, you know what to reconsider with your clinician.
You now have personal evidence to keep, confirm, or discuss with your clinician.
Phoenix lowers confidence in this candidate and helps you choose the next test.
What becomes possible next?
Phoenix learns how interventions perform for your genetics, baseline, environment, adherence, and real-life context. With consent, the study gains one anonymized data point.
The more well-measured experiments you run, the less Phoenix relies on population averages alone.
Phoenix AI already learns from published APOE4 research, clinical-trial evidence, Phoenix Member data, and your own results.
What appears to work for people like you may be worth testing for you. What appears to work for you may help someone similar ask a better question.
Help yourself find what works for you, and help APOE4 carriers around the world advance real-world research. Donations help Phoenix run more prospective n=1 studies, strengthen this shared learning loop, and turn one member's result into a better question for the next.
To support the work, email kevin@thephoenix.community.
A Phoenix check-in is a short, member-entered snapshot of daily life: sleep quality, energy, mood, mental sharpness, calm or stress, and overall wellbeing. It is subjective, so Phoenix interprets it beside objective records rather than alone.
Data were analyzed independently three times, adjudicated, and rerun against the underlying records.
A lab, wearable measure, cognitive task, or check-in before the change.
A supplement, medication, behavior, or protocol begins.
Was it taken? How often? What else changed at the same time?
What changed next, when, and by how much?
Does another eligible Phoenix Member move in the same direction?
The signals above are the starting point. The next step is a pre-planned experiment that changes one thing, measures adherence, retests the outcome, and updates what Phoenix knows about you.
Which intervention moved your ApoB, and did the combination do more than either alone?
Medication choices and any sequential add-on design remain clinician-guided.
Research opportunity
44 Phoenix Members have recent ApoB above 70 mg/dL and no lipid medication logged.
Measure: ApoB, LDL-C, non-HDL-C, adherence, diet, weight, and every dated intervention change.
Does it change your cognitive performance, your energy, both, or neither?
Repeated baselines help separate an intervention signal from practice effects and better days.
Measurement base
Phoenix already has 167 completed cognitive sessions, but no closed intervention sequence.
Measure: Repeated cognitive tasks, daily energy, sleep, dose, adherence, and a pre-set 12-week endpoint.
Does it improve triglycerides and cognition enough to justify the time for you?
A prospective design can test the intervention itself instead of comparing naturally active days.
Signal to challenge
Across 15 members, higher-activity days averaged 6,882 more steps. The next-day analysis was null.
Measure: Assigned sessions, heart-rate zone, adherence, triglycerides, sleep, and repeated cognition.
Externally formatted and complete. The separate report will open after its final release review.
Ask for the methods, evidence ledger, or a conversation about prospective study design.
Start with Phoenix's seven-minute assessment to join. Members can connect a baseline, a change, adherence, follow-up, and the result. Each result can help Phoenix AI improve what it suggests testing next, for you and for carriers with a similar profile. Together, we are building Phoenix's goal: the largest ongoing member-led longitudinal study of how APOE4 carriers beat the odds.